Vaccination protocol and PC challenge. Male 6-to 8-week-old BALB/c mice were depleted of CD4 cells as previously described (13, 16) by administration of 0.3 mg GK1.5, a depleting anti-CD4 monoclonal antibody (17) . This dose of GK1.5 results in over 97% depletion of CD4 + T cells in the spleen, thymus, and lung, as measured by staining with RM4-4 (BD Pharmingen), an anti-CD4 antibody that is not blocked by GK1.5. Three days after CD4 depletion, subgroups of mice were vaccinated with 5 × 10 4 DCs in 100 ml PBS injected intravenously. Mice received PBS DCs only, DCs pulsed with PC, DCs transduced with AdLuc and unpulsed, DCs transduced with AdLuc and pulsed with PC, DCs transduced with AdCD40L, or DCs transduced with AdCD40L and pulsed with PC (n = 8-12 per group, split into two separate experiments).
To assess in vivo B cell responses, mice were bled at 4 weeks for serum anti-PC antibody titers. As a positive control, a subgroup of normal 6-to 8-week-old BALB/c mice were immunized subcutaneously with 25 µg of PC antigen in CFA (Sigma Chemical Co., St. Louis, Missouri, USA) followed by injection of 25 µg of PC antigen in IFA. Two weeks after vaccination, mice were challenged with 2 × 10 5 PC cysts intratracheally. Mice were sacrificed at 2-4 weeks to assess intensity of PC infection by measuring PC organism burden by TaqMan PCR (Applied Biosystems, Foster City, California, USA), which measures copy number of PC ribosomal RNA (see below), as well as by Gomori methanamine silver (GMS) stain, as previously described (18) (19) (20) . For adoptive transfer studies, 6-to 8-week-old male BALB/c mice were CD4-depleted with GK1.5 and 3 days later received 300 µl of immune serum or splenocytes (from mice previously immunized with ADCD40L-modified DCs pulsed with PC), or unimmunized serum or splenocytes (from mice receiving DCs only or AdLuc-modified DCs pulsed with PC). Twenty-four hours later all mice were challenged with 2 × 10 5 PC cysts. Mice were sacrificed at 4 weeks for intensity of PC infection by TaqMan PCR or GMS stain.
RNA isolation and TaqMan probes and primers for PC rRNA. Total RNA was isolated from the right lungs of infected mice by a single-step method using TRIZOL reagent (Life Technologies Inc., Rockville, Maryland, USA). As a standard for the assay, a portion of PC muris rRNA (GenBank accession no. AF257179) was cloned into PCR2.1 (Invitrogen Corp., Carlsbad, California, USA), and PC rRNA was produced by in vitro transcription using the T7 RNA polymerase. The template was digested with RNase-free DNase, quantitated by spectrophotometry, and aliquoted at -80°C until further use. The TaqMan PCR primers for mouse PC rRNA are 5′-ATG AGG TGA AAA GTC GAA AGG G-3′ and 5′-TGA TTG TCT CAG ATG AAA AAC CTC TT-3′. The probe was labeled with a reporter fluorescent dye, 6-carboxyfluorescein (6FAM), and the sequence was 6FAM-AACAGCCCAGAATAAT-GAATAAAGTTCCTCAATTGTTAC-TAMRA. Real-time PCR was carried out using one-step TaqMan RT-PCR reagents (Applied Biosystems). The PCR amplification was performed for 40 cycles, with each cycle at 94°C for 20 seconds and 60°C for 1 minute, in triplicate using the ABI Prism 7700 SDS (Applied Biosystems). The threshold cycle values were averaged from the values obtained from each reaction, and data were converted to rRNA copy number by using a standard curve of known copy number of PC rRNA. This assay has a correlation coefficient higher than 0.98 and over eight logs of PC RNA concentration and correlates with viable PC since both heat killing and exposure to trimethoprim/suflamethoxazole ablate the signal. PC ELISA and Western blot. To determine anti-PC IgG titers, ELISA plates (Corning Inc., Corning, New York, USA) were coated with 100 ng of PC antigen per well in carbonate buffer pH 9.5, overnight. Plates were washed with PBS + 0.05% Tween-20 (wash buffer) and blocked with BSA and 2% milk. After washing, serial dilutions of serum were added to each well and incubated for 1 hour at room temperature. After washing, 100 µl of 1:1000 alkaline phosphatase-conjugated goat anti-mouse IgG (Bio-Rad Life Science Research Group, Hercules, California, USA) was added and incubated for 1 hour at room temperature. After washing, the plates were developed using Sigma 104 substrate tablets (Sigma Chemical Co.) in diethanolamine buffer and the absorbance at 490 nm was determined. For Western blotting, 100 µg of PC antigen per lane was separated on SDS-PAGE and transferred to PVDF membrane (Millipore Corp., Bedford, Massachusetts). The membrane was blocked with skim milk and cut into strips followed by incubation with 1:100 dilution of mouse serum from the different groups of vaccinated mice. The blot was developed by incubation with a secondary alkaline phosphatase-conjugated goat anti-mouse IgG (BioRad Life Science Research Group) and BCIP/NBT reagent (Bio-Rad Life Science Research Group).
Results

Activation of DCs by AdCD40L.
To assess viability and function of AdCD40L, bone marrow was harvested and DCs were derived by culturing the cells in GM-CSF and IL-4 for 6 days as outlined in Methods. DCs that were transduced with AdCD40L secreted significantly greater amounts of IL-12 p70 24 hours after transduction (1,110 ± 198 pg/ml, n = 4-6, P < 0.001) compared with AdLuc-or mock-transduced DCs (< 15 pg/ml, n = 4-6). Moreover, more than 90% of these cells were shown to express CD40L by flow cytometry (data not shown). These data are similar to those reported by Kikuchi and colleagues (12) .
AdCD40L-modified DCs as a CD4-independent vaccine against PC. We next assessed in vivo protection of AdCD40L-modified DCs pulsed with PC by administering a single dose of 5 × 10 4 DCs intravenously. Vaccinated or control mice were then challenged with PC 2 weeks after vaccine administration and infection was scored by both TaqMan and GMS stain. Although we observed protection, as measured by a decrease in PC rRNA copy number, of approximately one log, there were readily detectable PC cysts in the lung (but in reduced numbers) in the vaccinated group. Since serum antibody titers were only in the 1:128-to-1:256 range, we administered two vaccines 2 weeks apart (Figure 1a) .
Administering a series of two vaccines 2 weeks apart to CD4-depleted mice resulted in a significant induction of anti-PC IgG in the group given AdC40L-modified DCs pulsed with PC, compared with respective control groups (Figure 1b) . Moreover, these 4-week titers were similar to those achieved in CD4-intact mice vaccinated with PC antigen in CFA and IFA given 2 weeks apart (Figure 1b) . To assess in vivo protection, these mice were challenged with 2 × 10 5 PC cysts intratracheally and sacrificed at 2 and 4 weeks to assess intensity of PC infection. All mice received weekly GK1.5 to ensure continued CD4 depletion. CD4-depleted mice receiving a series of two vaccines with AdCD40L-modified DCs pulsed with PC showed a significant reduction in PC organism burden at both 2 and 4 weeks compared with control mice (Figure 2 ). Mice vaccinated with AdLuc-modified DCs pulsed with PC showed protection at 2 weeks but not at 4 weeks. This may be due to a low level of antibody, produced by activated DCs alone.
Adoptive transfer of CD4-depleted splenocytes or serum confers protection against PC. In order to determine whether protection from PC infection in the absence of CD4 + T cells was mediated by humoral or cellular immunity, we performed adoptive transfer experiments into recipient CD4-depleted mice. BALB/c mice were treated with GK1.5 and 3 days later received 300 µl of serum intravenously from vaccinated mice or the various control groups of mice. Another group of CD4-depleted mice received 10 7 splenocytes by intraperitoneal injection, from the same vaccinated or control mice as used in the serum transfer experiments. Twenty-four hours later mice were challenged with 2 × 10 5 PC cysts intratracheally; they were sacrificed 4 weeks later to determine intensity of PC infection. The splenocyte preparations were verified to have less than 1% CD4 + cells by staining with clone RM4-4 that is not blocked by GK1.5. Mice that received serum or splenocytes from mice previously vaccinated with AdCD40L-modified DCs pulsed with PC demonstrated significant protection compared
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The with control mice as measured by PC rRNA copy number and GMS staining of lung sections ( Figures  3a and 4) . Moreover, adoptive transfer of serum was equally as effective as, if not more effective than, CD4-depleted splenocytes alone in providing protection to CD4-depleted mice, demonstrating that humoral antibody is critical for the protective effect.
Protective serum from AdCD40L-modified DC-vaccinated mice demonstrates a restricted IgG response. To assess the specificity of the protective antibody response, serum from vaccinated and control groups was used at a 1:100 dilution to blot against PC antigen separated by SDS-PAGE. Protective serum from AdCD40L/DC/PC-vaccinated mice reacted predominantly with a 55-kDa antigen of PC (Figure 3b) , whereas adjuvant immunized mice demonstrated a polyclonal response. No immunoreactivity was detected at a 1:100 dilution in DC control vaccinated mice (Figure 3b and data not shown).
Discussion
There is a critical need to develop CD4-independent vaccines for opportunistic infections, as the number of immunocompromised hosts is increasing due to HIV infection, as well as iatrogenic causes such as chemotherapy. One strategy is to define the factors that mediate CD4 + T cell help and provide therapeutic replacement of these factors. Toward this end, we have previously demonstrated that overexpression of IFN-γ, a potent Th1 cytokine produced by CD4 + T cells, can result in eradication of PC in the absence of CD4 + T cell help (13) .
Another molecule expressed on activated CD4 + T cells that is critically important for costimulation and CD4 + T cell help is CD40L. CD40L is expressed on activated T cells and allows DCs to interact directly with CD8 + cytotoxic T cells (21, 22) or B cells (23) . Kikuchi and colleagues have demonstrated that CD40L gene-modified DCs pulsed with Pseudomonas aeruginosa (PA) could stimulate naive B cells to produce anti-PA antibodies (12) and confer protection against PA challenge. The studies described in this paper extend these studies to the most common AIDS-defining pathogen, PC, which is critically dependent on CD4 + T cell status.
Interestingly, a finding observed in this study that was not observed in the study by Kikuchi and colleagues in the PA model was that there was a low level of anti-PC IgG generated in some of the DC control groups -namely, AdCD40L-modified DCs, which were not pulsed, and AdLuc-modified DCs that were or were not pulsed (Figure 3) . However, in the bacterial model, mice succumb to infection in a few days, whereas PC is a chronic infection that can persist for 8-12 weeks in CD4-depleted BALB/c mice. Thus, one possibility is that unpulsed DCs, after undergoing adenovirus transduction that can activate and mature DCs (24, 25) , migrate to the lung and pick up antigen in vivo, which could result in increased protection.
Toward this end, we have examined migration of DCs modified with an adenovirus expressing eGFP and can detect these cells in the lungs of mice 24 hours after intravenous administration (data not shown).
Furthermore, the IgG response generated by AdCD40L-modified DC technology was restricted to a 55-kDa antigen of PC which is protective upon adoptive transfer. These data suggest that an optimal humoral response, potentially to the 55-kDa antigen of PC (8, 26) , is clearly protective against PC. In support of this is the fact that uMT mice, which are deficient in B cells, are susceptible to PC (5). Moreover, immunization with the major surface glycoprotein (6), p55 PC antigen (9), or whole PC given by an intranasal route (8) has been shown to provide protection in animal models after subsequent immunosuppression and PC challenge. However, these are the first data to our knowledge of successful vaccination of CD4-deficient hosts against PC. Furthermore, the restricted antigen response suggests that this technology could be used for in vivo screening of protective antigens in a CD4 + T cell-independent fashion.
Future experiments will determine the isotype of antibody that confers protection, although data from Garvy and colleagues suggest that antibodies derived from either Th1 or Th2 stimulation are protective (27) ; moreover, it will be important to further characterize immunodominant antigens responsible for this effect. It is likely critical that this technology, to be effective in the setting of HIV infection, requires normal DC function. It has been reported that DC function, particularly chemotaxis and susceptibility to apoptosis, may be deranged in the context of HIV infection (28, 29) . However, pox virus-activated DCs can elicit CD4 and CD8 responses in chronically HIV-infected individuals (30) . Thus, targeting DCs ex vivo or in vivo with peptide or a DNA vaccine approach with CD40L as an adjuvant may ultimately induce therapeutic vaccine responses in high-risk individuals.
